Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 191

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 191
---
 SHARE CAPITAL</div>

The following description
of our share capital and provisions of our amended and restated articles of association which will be effective upon the completion of
this offering are summaries and do not purport to be complete. By becoming a shareholder in our Company, you will be deemed to have notice
of and consented to these provisions of our articles of association as amended and restated.

Authorized Capital

Upon the closing of this
offering, our authorized share capital will consist of Ordinary Shares, par value NIS 0.01 per share, of which Ordinary Shares will be
issued and outstanding (assuming that the Representative does not exercise its option to purchase additional Ordinary Shares).

All of our Ordinary Shares
have identical voting and other rights in all respects. All of our issued and outstanding Ordinary Shares are duly authorized, validly
issued, fully paid and non-assessable. Our amended and restated articles of association to be in effect upon completion of this offering
and the laws of the State of Israel do not restrict the ownership or voting of Ordinary Shares by non-residents of Israel, except with
respect to citizens of countries that are, or have been, in a state of war with Israel.

Preferred Shares

Upon the consummation of
this offering and the effectiveness of our amended and restated certificate of incorporation that will become effective immediately prior
to the consummation of this offering, we will have no authorized or outstanding preferred shares.

Each currently outstanding
Series A Preferred Share, Series B Preferred Share, Series C Preferred Share, Series D-1 Preferred Share and Series D-2 Preferred Share,
each a Preferred Share, is convertible, at the option of the holder at any time, and without the payment of additional consideration
by the holder into the number of Ordinary Shares as is determined by dividing the original issue price for such Preferred Share by the
conversion price that is in effect at the time of conversion. The initial conversion price is the original issue price for such Preferred
Shares. The original issue price for each Preferred Share is as follows: Series A Preferred Share was $12.50 per share, Series B Preferred
Share was $28.00164 per share, Series C Preferred Share was $28.73347 per share, Series D-1 Preferred Share was $50.68 per share and
Series D-2 Preferred Share was $38.01 per share, or Original Issue Price. The applicable conversion price of each is subject to adjustment
upon any future stock splits or combinations, dividends